Talecris Biotherapeutics Offers $550M In Senior Notes

Law360, New York (October 13, 2009, 5:02 PM EDT) -- Talecris Biotherapeutics Holdings Corp. has announced it will offer in a private placement $550 million in senior notes due in 2016.

Talecris will use the offering's proceeds to repay first- and second-lien term loans, repay some of the borrowings under its revolving credit facility, and pay related fees and expenses, the company said in a statement Tuesday.

The law firms representing Talecris in this transaction, if any, were not available at the time of publication.

On Oct. 6, Talecris closed its initial public offering of shares...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.